Evidence-Based Oncology™ (EBO) spoke with TailorMed's Ian Manners about the financial assistance and consumer protection landscape, and what the cost of cancer care means to patient experience and outcomes.
Interview by Mary Caffrey
Advertisement
Articles by Interview by Mary Caffrey
Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.
Roger M. Lyons, MD, Discusses 10-Year Review of MDS Patient Data From the Community Oncology Setting
Evidence-Based Oncology™️ spoke with Lyons about the creation of this real-world data set and the pros and cons of different treatments for MDS.
An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD
4
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
5